Rystiggo
What Rystiggo is used for
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Rystiggo
- Active substance
- rozanolixizumab
- Disease area
- Myasthenia Gravis
- Medicine group
- Immunosuppressants;neonatal fragment crystallizable receptor (FcRn) inhibitors
- ATC code
- L04AL02
- Marketing authorisation holder
- UCB Pharma
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Rystiggo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rystiggo used for?
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
What is the active substance in Rystiggo?
Rystiggo contains rozanolixizumab.
Who makes Rystiggo?
The EU marketing authorisation holder is UCB Pharma.
Is Rystiggo an orphan medicine?
Yes. Rystiggo is designated an orphan medicine in the EU, for a rare disease (Myasthenia Gravis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU